Kids From Poorer Homes May Have Worse Outcomes If MS Strikes

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 29, 2024.

By Ernie Mundell HealthDay Reporter

FRIDAY, Nov. 29, 2024 -- A child from a poorer neighborhood is more prone to severe illness once they develop multiple sclerosis (MS) compared to children growing up in more affluent areas, new research shows.

The study of 138 MS patients who'd been diagnosed before the age of 18 revealed that kids from less advantaged neighborhoods showed larger volumes of inflammation and brain tissue loss, compared to those from better-off locales.

“Our findings suggest that social disadvantage in childhood can have lasting effects on MS severity,” said study co-author Dr. Kimberly O’Neill of New York University Grossman School of Medicine in New York City.

“Childhood is a critical time for exposure to environmental factors associated with increased susceptibility to MS, such as passive smoke, pollution and low sunlight exposure," she explained.

The findings were published Nov. 27 in the journal Neurology.

As O'Neill's group noted, MS is rare in kids: Just 5% of cases arise before the age of 18. The children in the new study had all been diagnosed for at least four years prior to joining the investigation.

All of them underwent brain scans looking for MS-linked brain damage.

According to a journal news release, the researchers also collected data on "self-reported race and ethnicity, type of health insurance, parents’ education level, and the degree of neighborhood advantage or disadvantage."

Of those items, relying on public health insurance (rather than private) was most strongly linked to a child having more MS-linked brain inflammation and tissue loss, the researchers found.

A reliance on public insurance was also tied to more inflammatory lesions in the brain's white matter.

These children also had greater "black hole volumes" in the brain -- a sign of loss of brain tissue that's irreversible, according to the study authors.

Why such stark differences based on a family's source of insurance?

O'Neill's team said the difference wasn't due to how quickly a child was seen by a neurologist, how soon they began MS medications, or how effective those drugs were in slowing the disease.

“This suggests that access to health care does not explain the more severe disease burden shown in the brain scans of people in disadvantaged groups in our study,” O’Neill said in the news release.

It's clear that more research is needed to figure out the root causes of these disparities, she said.

“While these [study findings] are associations and not causes, many of these groups have historically been underrepresented in MS research and our work here is just beginning," O'Neill said.

Sources

  • American Academy of Neurology, news release, Nov. 27, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-11-30 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords